S&P Global Mobility Launches Mobility Pulse 360 to Help Automakers Optimize Incentives, Boost Sales, Adapt to Market Change and ensure they have the right programs in market for their customers with Confidence.

Rhea-AI Summary

S&P Global Mobility (NYSE:SPGI) launched Mobility Pulse 360 on Jan 16, 2026, a new analytics platform that combines in-market incentive programs, transaction price, unsold dealer inventory and sales into a single interface.

The platform uses real-time connected datasets to deliver granular insights by make, model, model year, fuel type and DMA, with weekly and month-end updates and coverage of over 90% of the US light-vehicle market. Mobility Pulse 360 is positioned to help OEM sales operations optimize incentives, pricing and inventory decisions and aims to surface efficiencies the company estimates could reach the hundreds of millions to billions spent on vehicle incentives.

Positive

• Integrates incentives, transaction price, dealer inventory and sales into one view
• Real-time connected datasets with weekly and month-end updates
• Granular insights by make/model/model year/fuel type and DMA
• Covers over 90% of the US light-vehicle market
• Aims to help optimize incentive spending that the company cites as potentially saving hundreds of millions to billions

Negative

• None.

Key Figures

New patients dosed: 5 patients Total patients dosed: 6 patients Second dose patients: 5 patients +5 more

8 metrics

New patients dosed 5 patients ACHIEVE Phase 2b trial, higher dose level

Total patients dosed 6 patients ACHIEVE Phase 2b, first dose at higher level

Second dose patients 5 patients Received second dose in ACHIEVE Phase 2b

Third dose patients 2 patients Received third dose in ACHIEVE Phase 2b

Dose volume 5 mL per dose Each TCB008 dose in ACHIEVE Phase 2b

Cells per dose 230 million gamma delta T cells Maximum cells in each 5 mL dose

Total cells over course Approximate 1 billion cells Over four doses per patient in ACHIEVE

Maximum dose count 4 possible doses Treatment course per patient in ACHIEVE Phase 2b

Market Reality Check

Price: $0.5000 Vol: Volume 1,142,980 is at 0....

normal vol

$0.5000 Last Close

Volume Volume 1,142,980 is at 0.81x the 20-day average of 1,410,557, indicating subdued trading ahead of this release. normal

Technical Shares at $545.00, trading above the 200-day MA of $511.12 and about 5.9% below the $579.05 52-week high.

Peers on Argus

Core peers like MCO (+0.77%), ICE (+3.91%), CME (+1.84%), MSCI (+1.36%) and NDAQ...

Core peers like MCO (+0.77%), ICE (+3.91%), CME (+1.84%), MSCI (+1.36%) and NDAQ (+2.02%) showed positive moves, but no peers appeared in the momentum scanner and pre-news SPGI moved only +0.52%, suggesting stock-specific rather than a strong sector-wide momentum move.

Common Catalyst Only one peer (CME) had same-day news, focused on crypto derivatives expansion, which is not directly related to SPGI’s mobility product launch theme.

Historical Context

5 past events · Latest: Jan 12 (Neutral)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Business divestiture	Neutral	+0.5%	Completion of EDM and thinkFolio sale with immaterial financial impact.
Jan 09	Earnings scheduling	Neutral	+0.1%	Announcement of Q4 and full-year 2025 results release and call date.
Jan 08	Sector study	Neutral	+0.8%	Copper demand/supply study highlighting potential long-term deficits.
Jan 07	Dividend overview	Neutral	-0.4%	Report on Q4 and 2025 U.S. dividend payment increases and records.
Dec 30	Housing data	Neutral	-0.5%	Release of October 2025 Case-Shiller home-price indices.

Pattern Detected

Recent SPGI news over the last few weeks has generally seen small, aligned price moves, with no large positive or negative dislocations around announcements.

Recent Company History

Over the last few weeks, SPGI has reported several incremental developments. On Dec 30, 2025, its Case-Shiller home-price report showed modest U.S. home-price gains. A Jan 7, 2026 update from S&P Dow Jones Indices highlighted $13.1 billion in Q4 2025 net dividend increases and $46.4 billion for 2025. A copper study on Jan 8, 2026 outlined long-term supply-demand imbalances. The company then scheduled its Q4 and full-year 2025 earnings call for Feb 10, 2026 and completed the sale of its EDM and thinkFolio businesses on Jan 12, 2026. Each event was followed by relatively small price reactions.

Market Pulse Summary

This announcement highlights continued product and data innovation within SPGI’s broader franchise, ...

Analysis

This announcement highlights continued product and data innovation within SPGI’s broader franchise, set against a stock trading above its $511.12 200-day MA and below its $579.05 52-week high. Recent news, including divestitures, research studies, and index updates, has produced relatively small price reactions. Investors may focus on how new offerings integrate with existing analytics platforms, upcoming earnings on February 10, 2026, and any incremental regulatory or filing activity disclosed in recent Forms 3 and 4.

Key Terms

phase 2b, gamma-delta t cell therapies, monotherapy, open-label, +3 more

7 terms

phase 2b medical

"ACHIEVE Phase 2b trial ongoing in the UK."

Phase 2b is a stage in the development of a new medicine or treatment where researchers test its effectiveness and safety in a larger group of people. This step helps determine whether the treatment works well enough to move forward and if it has manageable side effects, which is important for investors because successful results can lead to potential approval and market opportunity.

gamma-delta t cell therapies medical

"developing platform allogeneic gamma-delta T cell therapies for cancer"

Gamma-delta T cell therapies are a type of immune-cell treatment that uses a specific group of white blood cells (gamma-delta T cells) engineered or expanded to seek out and kill cancerous or infected cells. Think of them as specially trained soldiers that can recognize threats in a different, more flexible way than conventional immune cells; for investors they matter because successful clinical results or regulatory approvals can create large market opportunities but also carry high scientific and development risk.

monotherapy medical

"TCB008 is potentially a game-changing monotherapy for blood cancers"

Monotherapy is a treatment approach that uses only one type of medicine or therapy to address a condition, instead of combining multiple options. For investors, understanding monotherapy matters because it can influence a company's development strategy, risk profile, and potential market size, especially if the single-treatment approach proves effective or faces limitations compared to combination therapies.

open-label medical

"The ACHIEVE UK clinical trial is an open-label, phase II study"

Open-label describes a situation where everyone involved in a study or process knows the full details, such as who is receiving a treatment or intervention. For investors, understanding whether a project or product is open-label helps gauge the level of transparency and potential biases, influencing trust and decision-making. It’s like knowing whether a test or experiment is conducted openly or behind closed doors.

phase ii medical

"The ACHIEVE UK clinical trial is an open-label, phase II study"

Phase II is the mid-stage clinical trial where a potential drug or medical treatment is tested in a larger group of patients to see if it works and to help determine the best dose and common side effects. For investors, Phase II results matter because they give the first meaningful evidence about effectiveness and safety—like a road test that shows whether a product has real promise before a much bigger, costly final trial and potential regulatory approval.

aml medical

"designed to evaluate the efficacy and effectiveness of TCB008 in patients with AML"

AML stands for anti-money laundering — the laws, rules and internal checks that banks and businesses use to spot and stop illicit cash flows, such as proceeds from crime or funding of illegal activities. Think of it as a security checkpoint for money: investors care because poor AML controls can lead to heavy fines, frozen assets and reputational harm that hurt profits and share value, while strong controls reduce legal and operational risk.

mds/aml medical

"patients with AML or MDS/AML, with either refractory or relapsed disease."

MDS/AML stands for myelodysplastic syndromes and acute myeloid leukemia, two related disorders in which the bone marrow’s blood-cell “factory” produces too few or abnormal blood cells and can progress to an aggressive blood cancer. For investors, these conditions matter because clinical trial results, regulatory approvals, safety concerns, or new treatment options can quickly change a company’s potential sales, costs and valuation—similar to how a breakthrough or setback in car safety could reshape demand for a vehicle maker.

AI-generated analysis. Not financial advice.

New platform is the first to offer an intuitive user interface with analytics built off real-time connected data that includes in market-incentive programs, transaction price, unsold dealer inventory and sales enabling faster, more confident strategic decisions in a rapidly changing market.

SOUTHFIELD, Mich., Jan. 15, 2026 /PRNewswire/ -- In response to persistent market volatility and increasing complexity within the automotive industry, S&P Global Mobility today announced the launch of Mobility Pulse 360. This new, industry-first platform directly addresses a critical challenge for automakers by integrating sales, dealer inventory, in market incentive programs, and transactional pricing data into a single, cohesive view. Mobility Pulse 360 is designed to equip Original Equipment Manufacturers (OEMs) with the clarity needed to make swift, data-driven decisions for their sales operations in a fast-moving environment.

By connecting these critical information streams, Mobility Pulse 360 unlocks a new layer of strategic intelligence, allowing OEMs to move from observing market trends to understanding the drivers behind them. For example, a user can now instantly visualize how a competitor's regional incentive change directly impacts their own inventory levels and sales share, all in one place. This capability is powered exclusively by S&P Global Mobility's comprehensive, internally sourced datasets, creating an unrivaled solution that combines a sophisticated platform with data recognized as the industry benchmark for accuracy and depth.

Automakers today face a convergence of pressures: intense competition, fluctuating consumer demand, and the intricate transition to electric vehicles. While rich data exists, it is often fragmented across different systems, creating delays and strategic blind spots. This makes it difficult to accurately plan inventory, optimize pricing, or structure effective incentive campaigns. Mobility Pulse 360 solves this by providing a holistic view of the market, turning disconnected data points into a powerful strategic asset.

"We've listened to our customers to better understand how to help their sales operations gain confidence in the decisions they make and visualize how their vehicles perform in a competitive market place. ," said Matthew Weiss, VP, Analytics & Pricing Solutions at S&P Global Mobility. " Mobility Pulse 360 is designed to solve their problems with intuitive UI, advanced Analytics all built on the industries best in month connected data that include in market incentive programs, transaction price, unsold dealer inventory and sales data. . The '360' in the name represents the complete, holistic perspective it provides—connecting an OEM's Sales Operations teams with  external market dynamics through intuitive user interface. This integrated view allows for smarter strategies and surgical tactical decisions. For instance, by optimizing inventory and incentive spending based on real-time competitive pressures, an OEM can uncover significant efficiencies. This not only strengthens their market position but also gives them the strategic levers to help address pressing industry issues, such as vehicle affordability for buyers. We're moving our clients from looking at a fragmented dashboard to having a full cockpit view of their business. Our goal is to help our customers optimize and find efficiencies to the hundreds of millions to billions they are spending in vehicle incentives"

Key capabilities of Mobility Pulse 360 include:

• Intuitive UI :  Easy to access complex datasets built with our customers in mind. Seamlessly integrates connected datasets, allowing teams to focus on strategy rather than data compilation.
• Advanced Analytics: Ability to accelerate strategic response and built off our real-time connected datasets offering intuitive insights in a rapidly changing and diverse market place. These include new views of measuring offered monthly payments, transaction level insights, dealer inventory measurement and how these all impact your share performance. These allow users to anticipate competitive actions by monitoring regional risks and fine-tune pricing strategies in response to market shifts.
• Real time Connected Data:   Industry leading granular datasets built off of our In market incentive programs, transaction price, dealer inventory and sales performance
• Granular, Actionable Detail: The platform provides insights by make, model, model year, fuel type, and geography (down to the DMA level), with weekly and month-end updates ensuring a current view of performance.
• Comprehensive Market Coverage: Mobility Pulse 360 offers exceptional insights into over 90% of the US light vehicle market, covering both premium and mainstream segments.

The launch of Mobility Pulse 360 marks a significant advancement in automotive analytics and reinforces S&P Global Mobility's commitment to providing essential intelligence.

For more information about Mobility Pulse 360, please visit:  S&P Global Mobility

About S&P Global Mobility: At S&P Global Mobility, we provide invaluable insights derived from unmatched automotive data, enabling our customers to anticipate change and make decisions with conviction. Our expertise helps them to optimize their businesses, reach the right consumers, and shape the future of mobility. We open the door to automotive innovation, revealing the buying patterns of today and helping customers plan for the emerging technologies of tomorrow.

S&P Global Mobility is a division of S&P Global (NYSE: SPGI). S&P Global is the world's foremost provider of credit ratings, benchmarks, analytics and workflow solutions in the global capital, commodity and automotive markets. With every one of our offerings, we help many of the world's leading organizations navigate the economic landscape so they can plan for tomorrow, today. For more information, visit www.spglobal.com/mobility.

Media Contact:
MobilityComms@spglobal.com

 

FAQ

What is Mobility Pulse 360 from S&P Global Mobility (SPGI)?

Mobility Pulse 360 is a platform that combines in-market incentive programs, transaction price, dealer inventory and sales into a single, real-time analytics interface.

When did S&P Global Mobility (SPGI) launch Mobility Pulse 360?

Mobility Pulse 360 launched on Jan 16, 2026.

How much US market coverage does Mobility Pulse 360 provide for SPGI customers?

The platform provides coverage for over 90% of the US light-vehicle market, across premium and mainstream segments.

What data granularity does Mobility Pulse 360 offer for SPGI clients?

It offers data by make, model, model year, fuel type and geography down to the DMA level, with weekly and month-end updates.

How can Mobility Pulse 360 affect OEM incentive and pricing decisions for SPGI customers?

By linking incentives, pricing, inventory and sales in real time, it aims to help OEMs fine-tune pricing and incentive spending and identify efficiencies in incentive budgets.